$2.37
+0.07 (+3.04%)
Open$2.34
Previous Close$2.30
Day High$2.41
Day Low$2.33
52W High$13.28
52W Low$7.14
Volume—
Avg Volume52.3K
Market Cap80.48M
P/E Ratio18.92
EPS$0.54
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+405.1% upside
Current
$2.37
$2.37
Target
$11.97
$11.97
$8.96
$11.97 avg
$15.34
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 51.54M | 48.92M | 53.08M |
| Net Income | -6,374,638 | -6,659,114 | -5,888,081 |
| Profit Margin | -12.4% | -13.6% | -11.1% |
| EBITDA | -7,191,271 | -7,364,625 | -7,497,793 |
| Free Cash Flow | -8,326,283 | -5,338,476 | -7,416,749 |
| Rev Growth | +3.4% | -7.2% | +0.9% |
| Debt/Equity | 0.61 | 0.70 | 0.59 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |